Oluwaseun Falade-Nwulia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8292232/publications.pdf

Version: 2024-02-01

56 papers 2,065 citations

430754 18 h-index 243529 44 g-index

57 all docs

57 docs citations

57 times ranked

3473 citing authors

#	Article	IF	CITATIONS
1	Nonadherence to Ledipasvir/Sofosbuvir Did Not Predict Sustained Virologic Response in a Randomized Controlled Trial of Human Immunodeficiency Virus/Hepatitis C Virus Coinfected Persons Who Use Drugs. Journal of Infectious Diseases, 2022, 225, 903-911.	1.9	4
2	Validation of a tool to assess effectiveness of peer-recruitment for hepatitis C testing and linkage to care among people who inject drugs. Drug and Alcohol Dependence, 2022, 230, 109177.	1.6	1
3	The impact of social network dynamics on engagement in drug use reduction programs among men and women who use drugs. Journal of Substance Abuse Treatment, 2022, 137, 108713.	1.5	2
4	A longitudinal study of vaccine hesitancy attitudes and social influence as predictors of COVID-19 vaccine uptake in the US. Human Vaccines and Immunotherapeutics, 2022, 18, 1-9.	1.4	33
5	Perceptions of network based recruitment for hepatitis C testing and treatment among persons who inject drugs: a qualitative exploration. International Journal of Drug Policy, 2021, 88, 103019.	1.6	7
6	Outcomes of acute hepatitis B virus (HBV) in HIV infection with and without HBV-active antiretroviral therapy. Aids, 2021, 35, 991-993.	1.0	3
7	Genomic diversity of SARS-CoV-2 during early introduction into the Baltimore–Washington metropolitan area. JCl Insight, 2021, 6, .	2.3	31
8	Behavioral and Attitudinal Correlates of Trusted Sources of COVID-19 Vaccine Information in the US. Behavioral Sciences (Basel, Switzerland), 2021, 11, 56.	1.0	27
9	The Influence of PrEP-Related Stigma and Social Support on PrEP-Use Disclosure among Women Who Inject Drugs and Social Network Members. AIDS and Behavior, 2021, 25, 3922-3932.	1.4	9
10	Impact of co-occurring drug use, hazardous alcohol use and mental health disorders on drug use patterns in people living with HIV and hepatitis C virus infection. Open Forum Infectious Diseases, 2021, 8, ofab520.	0.4	0
11	Progress and remaining challenges to address hepatitis C, other infectious diseases, and drug-related harms to improve the health of people who use drugs. International Journal of Drug Policy, 2021, 96, 103469.	1.6	7
12	HCV communication within ego-centric networks of men and women who inject drugs. Drug and Alcohol Dependence, 2021, 229, 109157.	1.6	4
13	Hepatitis C Virus Elimination Requires More Than Good Drugs. Clinical Infectious Diseases, 2020, 71, 1269-1270.	2.9	O
14	Correlates of hepatitis C viral clustering among people who inject drugs in Baltimore. Infection, Genetics and Evolution, 2020, 77, 104078.	1.0	11
15	Unreported alcohol use was common but did not impact hepatitis C cure in HIVâ€infected persons who use drugs. Journal of Viral Hepatitis, 2020, 27, 476-483.	1.0	5
16	Characterizing latent classes of social support among persons who inject drugs. Drug and Alcohol Dependence, 2020, 207, 107816.	1.6	3
17	Sharing the cure: Building primary care and public health infrastructure to improve the hepatitis C care continuum in Maryland. Journal of Viral Hepatitis, 2020, 27, 1388-1395.	1.0	9
18	Factors associated with phylogenetic clustering of hepatitis C among people who inject drugs in Baltimore. BMC Infectious Diseases, 2020, 20, 815.	1.3	9

#	Article	IF	CITATIONS
19	Hepatitis C treatment uptake among people who inject drugs in the oral directâ€acting antiviral era. Liver International, 2020, 40, 2407-2416.	1.9	19
20	Hepatitis C Virus Treatment: Simplifying the Simple and Optimizing the Difficult. Journal of Infectious Diseases, 2020, 222, S745-S757.	1.9	9
21	Public Health Clinic–Based Hepatitis C Treatment. American Journal of Preventive Medicine, 2020, 59, 420-427.	1.6	5
22	Racial Disparities in Overdose Prevention among People Who Inject Drugs. Journal of Urban Health, 2020, 97, 823-830.	1.8	35
23	Individual and network factors associated with HCV treatment uptake among people who inject drugs. International Journal of Drug Policy, 2020, 78, 102714.	1.6	19
24	Networkâ€based recruitment of people who inject drugs for hepatitis C testing and linkage to care. Journal of Viral Hepatitis, 2020, 27, 663-670.	1.0	18
25	A23â€fPopulation level diversification of hepatitis C viral strains over time among people who inject drugs in Baltimore, MD. Virus Evolution, 2019, 5, .	2.2	O
26	More than just availability: Who has access and who administers take-home naloxone in Baltimore, MD. PLoS ONE, 2019, 14, e0224686.	1.1	38
27	Hepatitis C Elimination in People With HIV Is Contingent on Closing Gaps in the HIV Continuum. Open Forum Infectious Diseases, 2019, 6, ofz426.	0.4	14
28	Barriers and facilitators of hepatitis C treatment uptake among people who inject drugs enrolled in opioid treatment programs in Baltimore. Journal of Substance Abuse Treatment, 2019, 100, 45-51.	1.5	49
29	Staying hepatitis C negative: A systematic review and metaâ€analysis of cure and reinfection in people who inject drugs. Liver International, 2019, 39, 2244-2260.	1.9	36
30	A Randomized Controlled Trial of Cash Incentives or Peer Support to Increase HCV Treatment for Persons With HIV Who Use Drugs: The CHAMPS Study. Open Forum Infectious Diseases, 2019, 6, ofz166.	0.4	34
31	Overlapping epidemics of alcohol and illicit drug use among HCV-infected persons who inject drugs. Addictive Behaviors, 2019, 96, 56-61.	1.7	11
32	HCV Screening and Treatment Uptake Among Patients in HIV Care During 2014–2015. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 559-567.	0.9	12
33	More than just availability: Who has access and who administers take-home naloxone in Baltimore, MD., 2019, 14, e0224686.		O
34	More than just availability: Who has access and who administers take-home naloxone in Baltimore, MD., 2019, 14, e0224686.		0
35	More than just availability: Who has access and who administers take-home naloxone in Baltimore, MD. , 2019, 14, e0224686.		O
36	More than just availability: Who has access and who administers take-home naloxone in Baltimore, MD., 2019, 14, e0224686.		0

#	Article	IF	Citations
37	Understanding and addressing hepatitis C reinfection in the oral directâ€acting antiviral era. Journal of Viral Hepatitis, 2018, 25, 220-227.	1.0	75
38	Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clinical Infectious Diseases, 2018, 67, 1477-1492.	2.9	509
39	An Education and Field Experience Program to Increase Detection of Human Immunodeficiency Virus and Hepatitis C Virus. Progress in Community Health Partnerships: Research, Education, and Action, 2018, 12, 101-109.	0.2	4
40	High hepatitis C cure rates among black and nonblack human immunodeficiency virus–infected adults in an urban center. Hepatology, 2017, 66, 1402-1412.	3.6	39
41	Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection. Annals of Internal Medicine, 2017, 166, 637.	2.0	540
42	The Relationship between Neighborhood Disorder, Social Networks, and Indoor Cigarette Smoking among Impoverished Inner-City Residents. Journal of Urban Health, 2017, 94, 534-541.	1.8	8
43	The HCV care continuum does not end with cure: A call to arms for the prevention of reinfection. Journal of Hepatology, 2017, 66, 267-269.	1.8	17
44	Barriers to Hepatitis C Virus (HCV) Treatment Initiation in Patients With Human Immunodeficiency Virus/HCV Coinfection: Lessons From the Interferon Era. Open Forum Infectious Diseases, 2017, 4, ofx024.	0.4	22
45	Building a Community - Academic Partnership to Enhance Hepatitis C Virus Screening. , 2016, 6, .		6
46	Primary Care Providers Knowledge, Attitude and Practices Related to Hepatitis C Screening and Treatment in the Oral Direct Acting Antiviral Agents Era. , 2016, 06, .		18
47	Public health clinicâ€based hepatitis C testing and linkage to care in baltimore. Journal of Viral Hepatitis, 2016, 23, 366-374.	1.0	51
48	Senior Center-Based Hepatitis C Screening in Baltimore. Open Forum Infectious Diseases, 2016, 3, ofv217.	0.4	6
49	Incident Hepatitis B Virus Infection in HIV-Infected and HIV-Uninfected Men Who Have Sex With Men From Pre-HAART to HAART Periods. Annals of Internal Medicine, 2015, 163, 673-680.	2.0	28
50	1291Sexually Transmitted Diseases Clinic Based Hepatitis C Testing and Linkage to Care. Open Forum Infectious Diseases, 2014, 1, S49-S49.	0.4	1
51	Comparative Risk of Liver-Related Mortality From Chronic Hepatitis B Versus Chronic Hepatitis C Virus Infection. Clinical Infectious Diseases, 2012, 55, 507-513.	2.9	42
52	A 36-Year-Old Haitian Man With Coma, Acute Kidney Injury, Lactic Acidosis, and Respiratory Failure. Chest, 2012, 142, 798-801.	0.4	1
53	Host factors dictate control of viral replication in two HIV-1 controller/chronic progressor transmission pairs. Nature Communications, 2012, 3, 716.	5.8	57
54	Adverse interactions between antifungal azoles and vincristine: review and analysis of cases. Mycoses, 2012, 55, 290-297.	1.8	129

#	Article	IF	CITATIONS
55	Prolonged half-life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: avoiding a serious adverse drug interaction. Mycoses, 2011, 54, e877-e879.	1.8	17
56	Liver disease, HIV and aging. Sexual Health, 2011, 8, 512.	0.4	16